India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

The Indian pharmaceutical market (IPM) grew by 8.4 per cent in the financial year (FY) 2025 on the back of major therapies ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Switching to tirzepatide associated with hemoglobin A1c reduction and weight loss compared with escalating treatment with dulaglutide.

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

As diabetes cases soar in the US, physicians are sounding the alarm, especially in economically challenged regions. The push ...

Amy Schumer shared she quit Wegovy due to side effects like nausea but was "having a really good experience" with Mounjaro, ...

To what extent will health clinics go to keep selling in-demand weight-loss drugs now that the FDA has outlawed cheaper ...

Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and ...